Literature DB >> 9420028

In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.

J L Muñoz Bellido1, S Muñoz Criado, I García García, M A Alonso Manzanares, M N Gutiérrez Zufiaurre, J A García-Rodríguez.   

Abstract

The activities of ampicillin, ampicillin-sulbactam, amoxicillin, amoxicillin-clavulanic acid, ticarcillin, ticarcillin-clavulanic acid, piperacillin, piperacillin-tazobactam, aztreonam, and aztreonam-clavulanic against Stenotrophomonas maltophilia strains for which the MICs of penicillins and commercially available beta-lactam-beta-lactamase inhibitor combinations were higher than the breakpoints usually recommended for Pseudomonas aeruginosa in commercially available broth microdilution methods were tested by the agar diffusion, agar dilution, and broth microdilution methods. Time-kill curve studies were performed when discrepancies between these methods were observed. The MICs obtained by the commercially available broth microdilution method, the agar dilution method, and the broth microdilution method were almost identical. Twenty-five percent of the strains tested showed inhibition diameters of > or =15 mm for ticarcillin-clavulanic acid, and 43.7% of the strains tested showed inhibition diameters of > or =18 mm for piperacillin-tazobactam by the agar diffusion method. The time-kill curves for these strains confirmed the results obtained by dilution methods. Aztreonam-clavulanic acid (2:1) at concentrations of < or =16 microg/ml inhibited all of these strains (MIC range, 1 to 16 microg/ml). The time-kill curves confirmed this activity. The addition of piperacillin to this combination did not modify the MICs. The combination aztreonam-clavulanic acid-ticarcillin was two- to fourfold more active than aztreonam-clavulanic acid alone. We studied the inhibitory and bactericidal activities of the two most active combinations (aztreonam-clavulanic acid and aztreonam-clavulanic acid-ticarcillin) against the standard inoculum and 10 and 50 times the standard inoculum. Inoculum modifications did not modify the MICs. Both combinations showed good bactericidal activity against the standard inoculum. With 10 times the standard inoculum, minimum bactericidal concentration (MBC) results were heterogeneous (for 55% of the strains, MBCs were between the MIC and 4-fold the MIC, and for 45% of the strains MBCs were between 8- and >32-fold the MIC). With 50 times the standard inoculum, MBCs were at least 32-fold the MICs for all the strains tested.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9420028      PMCID: PMC164178     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia.

Authors:  J A García-Rodríguez; J E García Sánchez; J L Muñoz Bellido; M I García García; E García Sánchez
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

2.  Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors.

Authors:  L S Elting; N Khardori; G P Bodey; V Fainstein
Journal:  Infect Control Hosp Epidemiol       Date:  1990-03       Impact factor: 3.254

Review 3.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

4.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

5.  The barrier function of the outer membrane of Pseudomonas maltophilia in the diffusion of saccharides and beta-lactam antibiotics.

Authors:  E Yamazaki; J Ishii; K Sato; T Nakae
Journal:  FEMS Microbiol Lett       Date:  1989-07-01       Impact factor: 2.742

6.  Comparison of E test and agar dilution for antimicrobial susceptibility testing of Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  J D Yao; M Louie; L Louie; J Goodfellow; A E Simor
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

7.  Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal:  Diagn Microbiol Infect Dis       Date:  1991 May-Jun       Impact factor: 2.803

8.  Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates.

Authors:  W Cullmann
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

9.  Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia.

Authors:  R Paton; R S Miles; S G Amyes
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods.

Authors:  M Arpi; M A Victor; I Mortensen; A Gottschau; B Bruun
Journal:  APMIS       Date:  1996-02       Impact factor: 3.205

View more
  4 in total

1.  Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

Authors:  S Valdezate; A Vindel; E Loza; F Baquero; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 3.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

4.  Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.

Authors:  M Biagi; D Lamm; K Meyer; A Vialichka; M Jurkovic; S Patel; R E Mendes; Z P Bulman; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.